DOI: https://doi.org/10.22141/2224-0551.14.5.2019.177410

Possibilities of the diagnosis and prevention of diabetic nephropathy development in children with type 1 diabetes mellitus

A.M. Loboda, I.O. Shandyba

Abstract


The rapid increase in the prevalence of type 1 mellitus (DM) has made the study of this pathology in children a priority. Diabetic nephropathy (DN) is one of the most common complications of diabetes mellitus and is characterized by damage to the kidney vessels, development of glomerulosclerosis and chronic renal failure in the future. The asymptomatic course of the disease in the early stages complicates the diagnostic and prophylactic actions. Microalbuminuria develops 5–7 years after diagnosis of diabetes and is not the main indicator of kidney damage in the early stages of DN. Biomarkers play an important role in early diagnosis, analysis of the progression of the pathological process and adequate treatment. The purpose of the review is to study potential early biomarkers of DN and their structural and functional cha­racteristics. For writing the article, a search was made on the Scopus and Web of Science databases. The review contains information about 13 markers of functional impairment of the glomerular tubular apparatus of the kidney. The consequences of activation of oxidative stress, inflammatory and fibrotic processes at the level of the glomerular and tubular kidney apparatus are presented. A cascade of metabolic disturbances was considered, the trigger factor of which is hyperglycemia. The correlations, the expediency of using markers in patients of different ages and with different durations of type 1 diabetes were revealed. The biomarkers presented are candidates for the panel of diagnostic markers for DN and an addition to the existing standards for diagnosing lesions of the tubulointerstitial apparatus of the kidneys in case of DM. Prevention of diabetic complications remains an urgent task for modern researchers.

Keywords


review; diabetes mellitus type 1; children; diabetic nephropathy; biomarkers

References


IDF Diabetes Atlas-8th Edition. Available from: http://diabetesatlas.org/resources/2017-atlas.html. Accessed: 2017.

Campion C, Sanchez-Ferras O, Batchu S. Potential role of serum and urinary biomarkers in diagnosis and prognosis of diabetic nephropathy. Can J Kidney Health Dis. 2017 May 22;4:2054358117705371. doi: 10.1177/2054358117705371.

Uwaezuoke S. The role of novel biomarkers in predicting diabetic nephropathy: a review. Int J Nephrol Renovasc Dis. 2017 Aug 17;10:221-231. doi: 10.2147/IJNRD.S143186.

Omar M, Rezk M, El-Kafoury A, Kandil M. Microalbuminuria and glycated hemoglobin in children with type 1 diabetes mellitus. Alexandria Journal of Medicine. 2015;51(1):83-88. doi: 10.1016/j.ajme.2014.04.005.

Gluhovschi C, Gluhovschi G, Petrica L, et al. Urinary biomarkers in the assessment of early diabetic nephropathy. J Diabetes Res. 2016;2016:4626125. doi: 10.1155/2016/4626125.

Satirapoj B. Tubulointerstitial biomarkers for diabetic nephropathy. J Diabetes Res. 2018 Feb 8;2018:2852398. doi: 10.1155/2018/2852398.

Fiseha T, Tamir Z. Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol. 2016;2016:4647685. doi: 10.1155/2016/4647685.

Ahmed S, Hamed M. Kidney injury molecule-1 as a predicting factor for inflamed kidney, diabetic and diabetic nephropathy Egyptian patients. J Diabetes Metab Disord. 2015 Feb 25;14:6. doi: 10.1186/s40200-015-0131-8.

Maidannyk VG, Murenko AN. Informativity of modern of diabetic nephropathy in children. International Journal of Pediatrics, Obstetrics and Gynecology. 2014;5(3):55-70. (In Russian).

Kamijo-Ikemori A, Sugaya T, Ichikawa D, et al. Urinary liver type fatty acid binding protein in diabetic nephropathy. Clin Chim Acta. 2013 Sep 23;424:104-8. doi: 10.1016/j.cca.2013.05.020.

Mahfouz MH, Assiri AM, Mukhtar MH. Assessment of neutrophil gelatinase-associated lipocalin (NGAL) and retinol-binding protein 4 (RBP4) in type 2 diabetic patients with nephropathy. Biomark Insights. 2016 Feb 16;11:31-40. doi: 10.4137/BMI.S33191.

Velkov VV. Cystatin C and NGAL — the markers of preclinical renal dysfunction and subclinical acute kidney injury. Laboratornaya sluzhba. 2015;2:38-43. (In Russian). doi: 10.17116/labs20154238-43.

Papadopoulou-Marketou N, Skevaki C, Kosteria I, et al. NGAL and cystatin C: two possible early markers of diabetic nephropathy in young patients with type 1 diabetes mellitus: one year follow up. Hormones (Athens). 2015 Apr-Jun;14(2):232-40. doi: 10.14310/horm.2002.1520.

Hafez MH, El-Mougy FA, Makar SH, Abd El Shaheed S. Detection of an earlier tubulopathy in diabetic nephropathy among children with normoalbuminuria. Iran J Kidney Dis. 2015 Mar;9(2):126-31.

Nowak N, Skupien J, Smiles AM, et al. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int. 2018 May;93(5):1198-1206. doi: 10.1016/j.kint.2017.11.024.

Szirmay B, Kustan P, Horvath-Szalai Z, et al. Novel automated immune turbidimetric assay for routine urinary cystatin-C determinations. Bioanalysis. 2018 Mar 1;10(6):377-384. doi: 10.4155/bio-2017-0228.

Damman K, Masson S, Hillege HL, et al. Tubular damage and worsening renal function in chronic heart failure. JACC Heart Fail. 2013 Oct;1(5):417-24. doi: 10.1016/j.jchf.2013.05.007.

Zhang X, Zhou H, Li Y. Combined detection of urinary micro albumin, α1-microglobulin and N-acetyl-β-D-glucosaminidase in the early diagnosis of diabetic nephropathy. Pak J Med Sci. 2017 Nov-Dec;33(6):1324-1327. doi: 10.12669/pjms.336.13168.

Asare-Anane H, Twum F, Kwaku Ofori E, et al. Urinary lysosomal enzyme activities and albuminuria in Ghanaian patients with type 2 diabetes mellitus. Disease Markers. 2016;2016:2810639. doi: 10.1155/2016/2810639

Mise K, Hoshino J, Ueno T, et al. Prognostic Value of Tubulointerstitial Lesions, Urinary N-Acetyl-β-d-Glucosaminidase, and Urinary β2-Microglobulin in Patients with Type 2 Diabetes and Biopsy-Proven Diabetic Nephropathy. Clin J Am Soc Nephrol. 2016 Apr 7;11(4):593-601. doi: 10.2215/CJN.04980515.

Abuohashish HM, Ahmed MM, Sabry D, Khattab MM, Al-Rejaie SS. ACE-2/Ang1-7/Mas cascade mediates ACE inhibitor, captopril, protective effects in estrogen-deficient osteoporotic rats. Biomed Pharmacother. 2017 Aug;92:58-68. doi: 10.1016/j.biopha.2017.05.062.

Mizuiri S, Nishizawa Y, Hamanoue M, et al. ACE2- Ang 1-7-MAS axis in human diabetic nephropathy. J Nephrol Therapeutic. 2012;S2:005. doi:10.4172/2161-0959.S2-005.

Saif A, Soliman N. Urinary α1-microglobulin and albumin excretion in children and adolescents with type 1 diabetes. J Diabetes. 2017 Jan;9(1):61-64. doi: 10.1111/1753-0407.12383.

Monteiro MB, Thieme K, Santos-Bezerra DP, et al. Beta-2-microglobulin (B2M) expression in the urinary sediment correlates with clinical markers of kidney disease in patients with type 1 diabetes. Metabolism. 2016 Jun;65(6):816-24. doi: 10.1016/j.metabol.2016.02.012.

Ochieng J, Nangami G, Sakwe A, et al. Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes. Int J Mol Sci. 2018 Jul 29;19(8). pii: E2211. doi: 10.3390/ijms19082211.

Zhou ZW, Ju HX, Sun MZ, Chen HM, Fu QP, Jiang DM. Serum fetuin-A levels in obese and non-obese subjects with and without type 2 diabetes mellitus. Clin Chim Acta. 2018 Jan;476:98-102. doi: 10.1016/j.cca.2017.11.023.

Aroner SA, St-Jules DE, Mukamal KJ, et al. Fetuin-A, glycemic status, and risk of cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2016 May;248:224-9. doi: 10.1016/j.atherosclerosis.2016.03.029.

Wang H, Sama AE. Anti-inflammatory role of fetuin-A in injury and infection. Curr Mol Med. 2012 Jun;12(5):625-33.

Nigro E, Scudiero O, Ludovica Monaco M, et al. Adiponectin profile and Irisin expression in Italian obese children: association with insulin-resistance. Cytokine. 2017 Jun;94:8-13. doi: 10.1016/j.cyto.2016.12.018.

Fang H, Judd RL. Adiponectin regulation and function. Compr Physiol. 2018 Jun 18;8(3):1031-1063. doi: 10.1002/cphy.c170046.

Brunner HI, Gulati G, Klein-Gitelman MS, et al. Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus. Pediatr Nephrol. 2019 Jan;34(1):117-128. doi: 10.1007/s00467-018-4049-5.

Аhmedova SU, Daminova MN, Kadyrova ZS. Role of obesity in the progression of diabetic nephropathy in patients with diabetes mellitus. Mìžnarodnij endokrinologìčnij žurnal. 2016;6(78):87–90. doi: 10.22141/2224-0721.6.78.2016.81865. (in Russian).

Zeng XF, Lu DX, Li JM, et al. Performance of urinary neutrophil gelatinase-associated lipocalin, clusterin, and cystatin C in predicting diabetic kidney disease and diabetic microalbuminuria: a consecutive cohort study. BMC Nephrol. 2017 Jul 12;18(1):233. doi: 10.1186/s12882-017-0620-8.

Kim SS, Song SH, Kim JH, et al. Urine clusterin/apolipoprotein J is linked to tubular damage and renal outcomes in patients with type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2017 Aug;87(2):156-164. doi: 10.1111/cen.13360.

Park S, Mathis KW, Lee IK. The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord. 2014 Mar;15(1):45-53. doi: 10.1007/s11154-013-9275-3.






Copyright (c) 2019 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта